| Literature DB >> 29887162 |
Sara Mazzucco1, Linxin Li2, Lucy Binney2, Peter M Rothwell2.
Abstract
BACKGROUND: Percutaneous closure of patent foramen ovale (PFO) has been shown to be superior to medical treatment alone for prevention of recurrent stroke after cryptogenic transient ischaemic attack or non-disabling stroke in patients aged 60 years or younger. The justification for trials in older patients with transient ischaemic attack or stroke depends on whether PFO is shown to be associated with cryptogenic events at older ages, for which existing evidence is conflicting, and on the population burden of PFO-associated events. Therefore, we did a population-based screening study using contrast-enhanced transcranial Doppler (bubble-TCD) to detect probable PFO as indicated by a right-to-left shunt (RLS); we also did a systematic review and meta-analysis to compare our results with previous studies.Entities:
Mesh:
Year: 2018 PMID: 29887162 PMCID: PMC6004554 DOI: 10.1016/S1474-4422(18)30167-4
Source DB: PubMed Journal: Lancet Neurol ISSN: 1474-4422 Impact factor: 59.935
Baseline characteristics in patients with cryptogenic events versus events of known cause
| Cryptogenic (n=264) | Known cause (n=259) | p value | Cryptogenic (n=190) | Known cause (n=207) | p value | ||
|---|---|---|---|---|---|---|---|
| Age | 67·3 (7·3) | 71·9 (8·1) | <0·0001 | 74·0 (6·9) | 77·3 (8·3) | <0·0001 | |
| Male sex | 132 (50%) | 151 (58%) | 0·06 | 84 (44%) | 118 (57%) | 0·01 | |
| Index event | 0·0001 | 0·002 | |||||
| Transient ischaemic attack | 199 (75%) | 154 (59%) | .. | 150 (79%) | 134 (65%) | .. | |
| Ischaemic stroke | 65 (25%) | 105 (41%) | .. | 40 (21%) | 73 (35%) | .. | |
| Previous vascular event | |||||||
| Myocardial infarction | 10 (4%) | 29 (11%) | 0·002 | 9 (5%) | 27 (13%) | 0·004 | |
| Peripheral vascular disease | 3 (1%) | 21 (8%) | 0·001 | 2 (1%) | 20 (10%) | 0·0002 | |
| Transient ischaemic attack | 16 (6%) | 39 (15%) | 0·001 | 14 (7%) | 39 (19%) | 0·001 | |
| Stroke | 21 (8%) | 42 (16%) | 0·005 | 18 (9%) | 37 (18%) | 0·02 | |
| Known vascular risk factors | |||||||
| Hypertension | 139 (53%) | 164 (63%) | 0·01 | 120 (63%) | 144 (70%) | 0·18 | |
| Diabetes | 33 (13%) | 44 (17%) | 0·15 | 28 (15%) | 32 (15%) | 0·84 | |
| Hyperlipidaemia | 95 (36%) | 102 (39%) | 0·42 | 81 (43%) | 89 (43%) | 0·94 | |
| Valvular heart disease | 9 (3%) | 25 (10%) | 0·006 | 8 (4%) | 23 (11%) | 0·01 | |
| Cardiac failure | 3 (1%) | 17 (7%) | 0·005 | 3 (2%) | 16 (8%) | 0·004 | |
| Venous thrombosis | 8 (3%) | 14 (5%) | 0·18 | 6 (3%) | 14 (7%) | 0·10 | |
| Atrial fibrillation | 1 (<1%) | 111 (43%) | <0·0001 | 1 (1%) | 102 (49%) | <0·0001 | |
| History of smoking | 135 (51%) | 148 (57%) | 0·17 | 94 (49%) | 113 (55%) | 0·31 | |
| Current smoker | 35 (13%) | 41 (16%) | 0·4 | 17 (9%) | 16 (8%) | 0·67 | |
Data are mean (SD) or n (%). Data are stratified by age.
Including both history of atrial fibrillation and new atrial fibrillation detected after the index event. One patient with previous history of atrial fibrillation had successful ablation and was in sinus rhythm in repeated 5-day ambulatory cardiac monitoring.
Data missing for one patient.
Prevalence of RLS in patients with cryptogenic events compared with patients with events of known cause
| Age ≤60 years | 29/74 (39%) | 16/52 (31%) | 1·45 (0·68–3·07) | 0·33 |
| Age >60 years | 68/190 (36%) | 44/207 (21%) | 2·06 (1·32–3·23) | 0·001 |
| Total | 97/264 (37%) | 60/259 (23%) | 1·93 (1·32–2·82) | 0·001 |
| Age ≤60 years | 16/74 (22%) | 12/52 (23%) | 0·92 (0·39–2·15) | 0·85 |
| Age >60 years | 25/190 (13%) | 15/207 (7%) | 1·94 (0·99–3·80) | 0·05 |
| Total | 41/264 (16%) | 27/259 (10%) | 1·58 (0·94–2·66) | 0·08 |
Data are n/N (%) unless otherwise indicated. Data are stratified by age and size of the shunt. RLS=right-to-left shunt.
Studies included in the meta-analysis
| Di Tullio et al (1992) | Transthoracic echocardiography | Stroke | Neurology department | No | 45/146 (31%) | No | 61·8 (15·3) | <55 and ≥55 | 34% not referred for transthoracic echocardiography; 6·8% with inadequate transthoracic echocardiography |
| Hausmann et al (1992) | Transoesophageal echocardiography | Transient ischaemic attack or stroke (59·2%) | Not reported | Not reported | 65/103 (63%) | No | 52 (10) | <40 and ≥40 | Not reported |
| Jones et al (1994) | Transoesophageal echocardiography | Transient ischaemic attack or stroke (90·5%) | Hospital admission | Yes | 71/220 (33%) | No | 66 (13) | <50 and 50–69 | 27·6% |
| Handke et al (2007) | Transoesophageal echocardiography | Stroke | Stroke unit or intensive care unit | Yes | 227/503 (45%) | Yes | 62·2 (13·1) | <55 and ≥55 | 15·6% |
| De Castro et al (2010) | Transoesophageal echocardiography | Transient ischaemic attack or stroke (62·1% major stroke) | Stroke unit | Yes | 403/660 (61%) | Yes | 64·4 (13·5) | <55 and ≥55 | 38·9% |
| Force et al (2008) | Transoesophageal echocardiography | Transient ischaemic attack or stroke | Stroke unit | Not reported | 62/132 (47%) | Not reported | 70·7 (8·6) | ≥55 | Not reported |
| Yeung et al (1996) | Bubble-TCD | Transient ischaemic attack or stroke (70·5%) | Hospital admission | Yes | 116/210 (55%) | No | Men: 65 (range 12–86); Women: 63 (23–86) | ≤50, >50, and ≥70 | 51% |
| Serena et al (1998) | Bubble-TCD | Transient ischaemic attack or stroke (71·2%) | Neurology department | Yes | 53/203 (26%) | No | 64·8 (12·3) | <50, 51 to <70, and ≥70 | 20·9% (no temporal bone window) plus 1·9% (no Valsalva done) |
| OXVASC (2017) | Bubble-TCD | Transient ischaemic attack or non-disabling stroke (32·5%) | Stroke or transient ischaemic attack clinic service | Yes | 264/523 (50%) | Yes | 69·6 (13·4) | ≤60, >60, <70, and ≥70 | 8·6% |
TOAST=Trial of Org 10172 in Acute Stroke Treatment. Bubble-TCD=contrast-enhanced transcranial Doppler. OXVASC=Oxford Vascular Study.
Figure 1Prevalence of PFO in patients with cryptogenic events compared with patients with events of known cause
Meta-analyses of the prevalence of PFO in patients with cryptogenic events compared with patients with events of known cause, stratified by imaging modalities, (A) overall and (B) in older patients, according to study author's definition. PFO=patent foramen ovale. OR=odds ratio. Bubble-TCD=contrast-enhanced transcranial Doppler. OXVASC=Oxford Vascular Study. *Age cutoff points for the older group in different studies ranged between 40 and 60 years.
Figure 2Meta-analyses of the prevalence of PFO stratified by screening modality
PFO=patent foramen ovale. Bubble-TCD=contrast-enhanced transcranial Doppler. OXVASC=Oxford Vascular Study.